Valeant Pharmaceuticals Acquires Bausch + Lomb for $8.7 Billion

In a blockbuster deal that may reshape the eye care landscape, Canadian drugmaker Valeant Pharmaceuticals International Inc. announced it will acquire Bausch + Lomb for $8.7 billion in cash. Under the terms of the agreement, Valeant will pay about $4.5 billion to an investor group led by Bausch + Lomb owner Warburg ...

Full Story →